2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N7032
    Uridine 5′-diphosphoglucose disodium 28053-08-9 99.98%
    Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
    Uridine 5′-diphosphoglucose disodium
  • HY-B0006
    Carvedilol 72956-09-3 99.98%
    Carvedilol (BM 14190) is a non-selective β/α-1 blocker. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome.
    Carvedilol
  • HY-N0545
    Taurocholic acid sodium 145-42-6 99.82%
    Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.
    Taurocholic acid sodium
  • HY-148748
    Butyzamide 1110767-45-7 99.83%
    Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay.
    Butyzamide
  • HY-15551
    E-4031 113559-13-0 99.40%
    E-4031 is a selective hERG potassium channel blocker for use in class III anti-arrhythmic studies.
    E-4031
  • HY-16774
    Vericiguat 1350653-20-1 99.27%
    Vericiguat (BAY1021189) is a potent, orally available and soluble guanylate cyclase stimulator.
    Vericiguat
  • HY-14268
    Febuxostat 144060-53-7 99.87%
    Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout.
    Febuxostat
  • HY-B0561
    Spironolactone 52-01-7 99.81%
    Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC50=24 nM) and androgen receptor (IC50=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (Ang II)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type II diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca2+ channels to exert antihypertensive effects.
    Spironolactone
  • HY-108566
    U-46619 56985-40-1 ≥99.0%
    U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of Thromboxane A2 (HY-113350) (TXA2) and acts as a potent TXA2 (TP) agonist. U-46619 also is a RhoA agonist. U-46619 stimulates the activation of RhoA through TXA2 receptor activation.
    U-46619
  • HY-108865
    Alteplase 105857-23-6
    Alteplase (Actilyse; Activase), a tissue plasminogen activator prepared by recombination, is a thrombolytic agent that play important roles in acute ischemic stroke, pulmonary embolism, acute myocardial infarction, and occluded catheters.
    The product size below only indicate the effective content of Alteplase. The ratio of Alteplase effective content : total content = 1:46-1:50. The actual ratio depends on the batch.)
    Alteplase
  • HY-B0185
    Lidocaine 137-58-6 99.96%
    Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia.
    Lidocaine
  • HY-B0968A
    Trimetazidine 5011-34-7 99.84%
    Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor.
    Trimetazidine
  • HY-50667
    Apixaban 503612-47-3
    Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. Apixaban is in development for the prevention and treatment of various thromboembolic diseases.
    Apixaban
  • HY-N0115
    Gastrodin 62499-27-8 99.94%
    Gastrodin, a main constituent of a Chinese herbal medicine Tianma, has been known to display anti-inflammatory effects. Gastrodin inhibits ethanol-induced hepatocellular apoptosis. Gastrodin inhibits H2O2-induced ferroptosis through its antioxidative effect. Gastrodin can be used for study of dizziness, epilepsy, stroke and dementia.
    Gastrodin
  • HY-Y0882
    Hydroxylamine hydrochloride 5470-11-1 ≥99.0%
    Hydroxylamine hydrochloride is a selective Monoamine oxidase (MAO) inhibitor used for inhibiting of platelet aggregation. Hydroxylamine hydrochloride is an intermediate of nitrogen cycle in aerobic ammonium oxidizers microorganisms, such as ammonium oxidizing bacteria (AOB), ammonium oxidizing archaea (AOA) and complete ammonium oxidizing bacteria (comammox). Hydroxylamine hydrochloride impacts NO and N2O emissions by aerobic ammonium oxidizers microorganisms and inhibits nitrite oxidizing bacteria (NOB) activity.
    Hydroxylamine hydrochloride
  • HY-13687
    IKK 16 873225-46-8 99.88%
    IKK 16 is an orally active IKK inhibitor. IKK 16 shows IC50s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC50s of 153.9, 115, and 99.7 nM, respectively. IKK 16 is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway.
    IKK 16
  • HY-N0124
    Dioscin 19057-60-4 99.95%
    Dioscin (CCRIS 4123; Collettiside III) is a natural plant-derived steroidal saponin that has good anti-cancer activity against a variety of cancer cells. Dioscin causes DNA damage and induces apoptosis in HeLa and SiHa cells. Dioscin regulates ROS-mediated DNA damage and mitochondrial signaling pathways, exerting anticancer activity.
    Dioscin
  • HY-154848
    UCL-TRO-1938 2919575-27-0 99.98%
    UCL-TRO-1938 is a potent small molecule allosteric activator of PI3Kα with an EC50 value of approximately 60 μM. UCL-TRO-1938 can induce cell proliferation and has cardioprotective effects from ischaemia reperfusion injury and enhances nerve regeneration following nerve crush.
    UCL-TRO-1938
  • HY-P1902
    Cardiotoxin Analog (CTX) IV (6-12) 115722-23-1 99.95%
    Cardiotoxin Analog (CTX) IV (6-12) is a membrane active peptide that specifically targets negatively charged phospholipid membranes (such as phosphatidylserine and phosphatidylinositol). Cardiotoxin Analog (CTX) IV (6-12) was discovered in the venom of the Taiwan cobra. Cardiotoxin Analog (CTX) IV (6-12) is a chemically synthesized snake venom cardiotoxin that binds to cell membranes and embeds into lipid bilayers through hydrophobic interactions and electrostatic attraction, thereby destroying the stability of membrane structure. Cardiotoxin Analog (CTX) IV (6-12) can induce membrane lipid disorder and cell lysis, exhibiting hemolysis and cytotoxicity.
    Cardiotoxin Analog (CTX) IV (6-12)
  • HY-112461A
    NF449 octasodium 627034-85-9 ≥99.0%
    NF449 octasodium is a highly potent P2X1 receptor antagonist, with IC50s of 0.28, 0.69, and 120 nM for rP2X1, rP2X1+5, P2X2+3, respectively. NF449 octasodium is a Gsα-selective G Protein antagonist. NF449 octasodium suppresses the rate of GTP[γS] binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to Gs.
    NF449 octasodium
Cat. No. Product Name / Synonyms Application Reactivity